Insulet Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Baird Reiterates Outperform on Insulet (PODD) Following 4Q
February 26, 2019 8:51 AM ESTBaird analyst, Jeff Johnson, reiterated an Outperform rating and $118.00 price target on Insulet Corporation (NASDAQ: PODD) following the company's 4Q earnings report. 4Q revenue of $165M exceeded consensus of $162M.
While 4Q results were solid, shares look likely to open lower as 2019... More
Insulet (PODD) Tops Q4 EPS by 9c, Revenues Beat; Offers Q1 Revenue Mid-Point Guidance Below Consensus, FY19 Revenue Views Below Consensus
February 25, 2019 4:03 PM ESTInsulet (NASDAQ: PODD) reported Q4 EPS of $0.16, $0.09 better than the analyst estimate of $0.07. Revenue for the quarter came in at $164.8 million versus the consensus estimate of $162.46 million.
Fourth quarter 2018 revenue of $164.9 million, up 26% compared to $130.5 million in the prior year, exceeds guidance of $159 to $164 millionU.S. Omnipod revenue of $93.2 million, an increase of 22%International Omnipod revenue of... More